The consensus was that patients with BRAF wild-type melanoma should receive immunotherapy in the adjuvant setting, BRAF-mutant patients should be offered both options: PD1-blockade as well as dabrafenib and trametinib. The gene discussed is BRAF; the disease is melanoma.